Title
Hypertension and Alzheimer's disease: indirect effects through circle of Willis atherosclerosis.

Permalink
https://escholarship.org/uc/item/8b38g9k3

Journal
Brain communications, 2(2)

ISSN
2632-1297

Authors
Eglit, Graham ML
Weigand, Alexandra J
Nation, Daniel A
et al.

Publication Date
2020

DOI
10.1093/braincomms/fcaa114

Peer reviewed
Hypertension and Alzheimer’s disease: indirect effects through circle of Willis atherosclerosis

Graham M. L. Eglit,1 Alexandra J. Weigand,2 Daniel A. Nation,3,4 Mark W. Bondi1,5 and Katherine J. Bangen1,5

Hypertension is common among older adults and is believed to increase susceptibility to Alzheimer’s disease, but mechanisms underlying this relationship are unclear. Hypertension also promotes circle of Willis atherosclerosis, which contributes to cerebral hypoperfusion and arterial wall stiffening, two potential mechanisms linking hypertension to Alzheimer’s disease. To examine the role of circle of Willis atherosclerosis in the association between hypertension and Alzheimer’s disease neuropathology, we analysed post-mortem neuropathological data on 2198 decedents from the National Alzheimer’s Coordinating Center database [mean (standard deviation) age at last visit 80.51 (1.95) and 47.1% female] using joint simultaneous (i.e. mediation) modelling. Within the overall sample and among Alzheimer’s dementia decedents, hypertension was indirectly associated with increased neuritic plaques and neurofibrillary tangles through its association with circle of Willis atherosclerosis. Similar indirect effects were observed for continuous measures of systolic and diastolic blood pressure. These results suggest that hypertension may promote Alzheimer’s disease pathology indirectly through intracranial atherosclerosis by limiting cerebral blood flow and/or dampening perivascular clearance. Circle of Willis atherosclerosis may be an important point of convergence between vascular risk factors, cerebrovascular changes and Alzheimer’s disease neuropathology.
Introduction

Hypertension is believed to increase susceptibility to Alzheimer’s dementia (Skoog et al., 1996; Launer et al., 2000; Walker et al., 2017). However, the role of vascular risk factors in Alzheimer’s dementia pathophysiology remains unclear. Specifically, there is ongoing debate as to whether vascular risk factors contribute to the deposition of the neuritic plaques and neurofibrillary tangles (NFTs) that represent the pathological hallmarks of Alzheimer’s dementia (Hyman et al., 2012), lead to cerebrovascular changes that in turn lower the threshold for the clinical expression of Alzheimer’s dementia pathology, or operate through both mechanisms (Zlokovic, 2011; Chui et al., 2012).

Hypertension is among the most prevalent of these vascular risk factors, occurring in nearly one-third of adults and two-thirds of older adults worldwide (Mills et al., 2016). Hypertension is a risk factor for Alzheimer’s dementia (Walker et al., 2017) and has been linked to increased amyloid-β (Aβ) plaque burden (Sparks et al., 1995; Ashby et al., 2016), parahippocampal NFT density (Sparks et al., 1995) and in vivo brain imaging markers of Aβ deposition (Rodrique et al., 2013). In addition, elevated systolic and diastolic blood pressures have been associated with increased neurtic plaque density (Petrovitch et al., 2000), NFT density (Petrovitch et al., 2000; Arvanitakis et al., 2018), in vivo brain markers of Aβ deposition (Langbaum et al., 2012; Toledo et al., 2012) and reduced glucose metabolism in Alzheimer’s dementia-vulnerable brain regions (Langbaum et al., 2012).

Several candidate mechanisms linking hypertension to Alzheimer’s dementia have been proposed. Chronic hypertension promotes inward vascular remodelling (Heagerty et al., 1993) and alters autoregulation mechanisms of the cerebrovasculature (Matsushita et al., 1994; Jennings et al., 2005), rendering the brain susceptible to cerebral hypoperfusion and reduced blood–brain barrier integrity. This cerebrovascular dysfunction may in turn lead to Aβ oligomerization (Wang et al., 2010), altered processing of the Aβ protein precursor (Tesco et al., 2007; Zhang et al., 2007; Li et al., 2009; Koike et al., 2010) and increased tau phosphorylation (Koike et al., 2010). Cerebral deposition of Aβ may be further exacerbated by hypertension-induced upregulation of the receptor for advanced glycation end products, which mediates Aβ influx from blood circulation into the brain (Carnevale et al., 2012). In addition to its effects on Aβ production and deposition, hypertension may also diminish Aβ clearance. Clearance of Aβ through the perivascular spaces is driven by recoil and reflection waves generated by the vessel wall (Schley et al., 2006), which are dampened when arteries stiffen due to chronic hypertension (Mitchell, 2014). Furthermore, concentrations of the Aβ-degrading enzymes angiotensin-converting enzyme and insulin degrading enzyme are reduced among hypertensive individuals, leading to diminished Aβ catabolism (Miners et al., 2011; Ashby et al., 2016).

Hypertension is also a known contributor to atherosclerosis, especially of the circle of Willis (Ingall et al., 1991). The circle of Willis is a ring of vessels surrounding the optic chiasm and pituitary stalk that connects the anterior and posterior circulations of the brain. According to the predominant response-to-injury model of atherosclerosis, elevated blood pressure causes swelling and stretching of blood vessel walls and consequent blood vessel endothelium injury, which in turn initiates a cascade of inflammatory events leading to atherosclerotic plaque formation (Ross, 1993). The circle of Willis may be especially vulnerable to atherosclerosis due to its curved shape and branching arteries, which tend to induce turbulent flow and increase endothelial injury (Chui et al., 2012).
and Chien, 2011). Circle of Willis atherosclerosis has itself been proposed as a risk factor for Alzheimer’s dementia (Kalback et al., 2004) and has been linked to increased neuritic plaque burden (Roher et al., 2003; Honig et al., 2005; Beach et al., 2007; Yarchoan et al., 2012), density of NFTs (Roher et al., 2003; Beach et al., 2007; Yarchoan et al., 2012) and in vivo neuroimaging markers of amyloid deposition (Hughes et al., 2014). Notably, some of the mechanisms linking hypertension to Alzheimer’s dementia are believed to be at least partly mediated through intracranial atherosclerosis, including those involving reduced cerebral blood flow and impaired perivascular AB clearance (Gupta and Iadecola, 2015). Taken together, this research suggests that the impact of hypertension on Alzheimer’s dementia pathogenesis may indirectly involve intracranial atherosclerosis.

To our knowledge, no research has attempted to disentangle whether hypertension contributes to Alzheimer’s dementia neuropathology directly or indirectly through intracranial atherosclerosis. Therefore, we used simultaneous joint statistical (i.e. mediation) modelling to investigate the direct effect of hypertension on Alzheimer’s dementia neuropathology as well as the indirect effect of hypertension through circle of Willis atherosclerosis. We hypothesized that hypertension would be associated with increased neuritic plaque and NFT pathology indirectly through its association with circle of Willis atherosclerosis.

Materials and methods

Participants

Observational data from the National Alzheimer’s Coordinating Center (NACC) database were used in this study. The NACC is a publicly available longitudinal dataset, with data collected from past and present National Institute on Aging-funded Alzheimer’s Disease Centers (ADCs) across the USA. Recruitment procedures vary across ADCs and as such, the NACC database is best characterized as a referral-based or volunteer case series. For this study, clinical data were gathered from the Uniform Data Set (UDS) and neuropathological data from the Neuropathological Data Set. Research using the NACC database was approved by the University of Washington Institutional Review Board. Informed consent was obtained at participating ADCs.

This analysis used data from 32 ADCs. Decedents from the NACC database included in the current study were required to have both UDS and Neuropathological Data Set data available as of the June 2018 data freeze. Decedents were additionally excluded for the following reasons: (i) missing data on Alzheimer’s dementia neuropathology variables, vascular neuropathology variables, vascular risk factor variables and demographic and clinical covariates; (ii) history of clinical stroke; and (iii) clinical diagnosis other than normal cognition, mild cognitive impairment (MCI) or Alzheimer’s dementia. After implementation of exclusion criteria, the final sample consisted of 2198 decedents [mean (standard deviation) age at last visit 80.51 (1.95) and 47.1% female] (see Supplementary Table 1 for descriptive statistics of the total sample).

Vascular risk factors

Hypertension

A combination of two measures from the NACC-UDS was used to determine hypertension diagnosis. The first of these measures was self-reported hypertension, for which the NACC-UDS provides three categories: absent, remote/inactive and recent/active. Decedents were deemed recent/active if they self-reported being currently hypertensive or if they still required active management and/or medication for hypertension, remote/inactive if they had a history of hypertension but were no longer hypertensive and not currently managing or taking anti-hypertensive medications and absent if they did not have a history of hypertension. The second was self-reported current use of anti-hypertensive medications. Decedents were classified as hypertensive if they (i) self-reported remote/inactive or recent/active hypertension or (ii) were currently using an anti-hypertensive medication. Continuous measures of systolic and diastolic blood pressure were available in a subset of the sample (n = 1647) and were evaluated in secondary analyses.

Other vascular risk factors

Several additional vascular risk factors are collected as part of the NACC-UDS, including history of hypercholesterolaemia, diabetes, heart attack, atrial fibrillation, congestive heart failure and transient ischaemic attack, as well as tobacco use within the past 30 days. All of these variables, with the exception of tobacco use within the past 30 days, are coded as absent, remote/inactive and recent/active. These variables were considered negative if absent and positive if remote/inactive or recent/active. All data on vascular risk factors, including hypertension-related variables, were obtained from each participant’s last visit prior to death.

Neuropathology

Alzheimer’s disease neuropathology

Neuropathological evaluations were conducted by individual ADCs according to their own protocols. As such, these protocols may differ between ADCs but relied on consensus guidelines and were collected following a standardized Neuropathology Form and Coding Guidebook. Alzheimer’s dementia neuropathology was graded according to Consortium to Establish a Registry for Alzheimer’s Disease criteria for neuritic plaques (Mirra et al., 1991) and Braak staging for NFTs (Braak
and Braak, 1991). Staining techniques differed across individual ADCs and included modified Bielschowsky, Gallyas stains, tau immunostains and other silver stains or thioflavin-S. Consortium to Establish a Registry for Alzheimer’s Disease neuritic plaque scores were graded as zero, mild, moderate or frequent. Neuritic plaques were evaluated in the middle frontal gyrus, superior and middle temporal gyri, inferior parietal lobule and possibly hippocampus/entorhinal cortex and occipital cortex. Braak staging was re-coded from the original seven stages to a four-category classification to improve inter-rater reliability and to facilitate interpretation (Nagy et al., 1998; Hyman et al., 2012). These categories were Braak Stage 0, Braak Stages I and II, Braak Stages III and IV, and Braak Stages V and VI. NFTs for Braak staging were evaluated in the transentorhinal/entorhinal region for Braak Stage I/II, limbic regions for Braak Stage III/IV, and neocortical regions including primary cortices for Braak Stage V/VI (Braak and Braak, 1991; Nagy et al., 1998).

**Vascular neuropathology**

The NACC-Neuropathological Data Set provides separate variables for circle of Willis atherosclerosis, cerebral amyloid angiopathy (CAA), infarcts/lacunes and microinfarcts. Circle of Willis atherosclerosis and CAA were rated as none, sparse (mild), moderate and frequent (severe). For atherosclerotic vascular pathology, ratings were based on the severity of intimal and medial fibrofatty atheromatous plaques in the circle of Willis. The assessment was qualitative and subjective and reflected an estimate of overall severity rather than with respect to an individual vessel. CAA was detected using amyloid stains (e.g. Congo red, thioflavin-S or Aβ immunostaining) in accordance with individual ADC protocols. For neuropathological evaluations prior to 2014, the assessment was qualitative and subjective and indicated an estimate of overall severity rather than an individual vessel. Further guidelines on grading severity were incorporated into the NACC Neuropathology Form and Coding Guidebook in January 2014. For post-2014 CAA semi-quantitative grading, none was defined as absent CAA, mild was defined as scattered positivity in parenchymal and/or leptomeningeal vessels, possibly in only one brain area, moderate was defined as intense positivity in many parenchymal and/or leptomeningeal vessels and severe was defined as widespread (more than one brain area) intensive positivity in parenchymal and leptomeningeal vessels. Grossly observed infarcts/lacunes and microinfarcts were classified as absent or present. Prior to January 2014, acute and old infarcts/lacunes and microinfarcts were not distinguished and regions assessed were not formally recorded. After January 2014, only old infarcts/ lacunes and microinfarcts were used for grading, which were evaluated in cerebral cortex, subcortical cerebral white matter and periventricular white matter, deep cerebral grey matter or internal capsule and brainstem or cerebellum.

**Clinical diagnosis**

All decedents received a clinical diagnosis at their last visit prior to death. Clinical diagnosis in the NACC database is based on multi-disciplinary consensus or clinical judgement using information from the comprehensive UDS evaluation. Clinical Dementia Rating Scale Sum of Boxes scores were available to further characterize disease severity across clinical groups.

**Other covariates**

Demographic characteristics of age at last visit, sex and race/ethnicity, as well as use of anti-hypertensive medications were collected as part of approximately annual UDS clinical evaluations. Owing to the small number of non-White decedents, race/ethnicity was classified as White versus non-White. Decedents with no apolipoprotein epsilon 4 allele (APOE ε4) were considered APOE ε4-negative and decedents with one or more ε4 alleles were considered APOE ε4-positive.

**Statistical analysis**

Initial analyses compared clinical groups on demographic, disease severity, vascular risk factor and neuropathologic-al characteristics using one-way ANOVA and chi-square tests.

Main analyses consisted of joint simultaneous (i.e. mediation) modelling of associations between hypertension, circle of Willis atherosclerosis and Alzheimer’s dementia neuropathology. Alzheimer’s dementia neuropathology was operationalized as either neuritic plaque or NFT pathology and models were specified separately for these two types of Alzheimer’s dementia neuropathology. Mediation analysis involves simultaneous estimation of a set of regression coefficients in order to evaluate pathways of influence between several variables. This is achieved by partitioning the total effect of an exposure variable (e.g. hypertension) on an outcome (e.g. Alzheimer’s dementia neuropathology) into an indirect effect through a mediator (e.g. circle of Willis atherosclerosis) and a direct effect of the exposure on the outcome. In the current study, the indirect effect of hypertension on Alzheimer’s dementia neuropathology was mediated through circle of Willis atherosclerosis and the direct effect reflected the association of hypertension on Alzheimer’s dementia neuropathology after adjusting for circle of Willis atherosclerosis. In the first regression equation, hypertension was entered to predict degree of circle of Willis atherosclerosis and in the second regression, hypertension and circle of Willis atherosclerosis were both included as predictors of neuritic plaque frequency or NFT density. Figure 1 presents a path diagram of modelled relationships between primary variables of interest. The indirect effect was calculated as the product
of the association of hypertension with circle of Willis atherosclerosis and of circle of Willis atherosclerosis with Alzheimer’s dementia neuropathology. Given the well-known non-normality of product term distributions (MacKinnon et al., 2007), a 95% bias-corrected bootstrapped confidence interval (CI) with 5000 bootstrap samples was used to evaluate indirect effect significance (Mackinnon et al., 2004). Models were conducted in the overall sample as well as separately on cases stratified by clinical group (normal cognition, MCI and Alzheimer’s dementia). Both circle of Willis atherosclerosis and neuritic plaque/NFT neuropathology variables were treated as ordinal and a logit link function with maximum likelihood estimation was used for parameter estimation. Parameter estimates were exponentiated and expressed as odds ratios (ORs). All paths in all models were adjusted for age at last visit, sex, non-White race, APOE ε4 positivity and presence of other vascular risk factors (hypercholesterolaemia, diabetes, current smoking, heart attack, atrial fibrillation, congestive heart failure and transient ischaemic attack). Owing to concerns about the consistency of neuropathological classifications across different ADCs, we also ran additional sensitivity analyses using alternative dichotomous classifications of circle of Willis atherosclerosis and Alzheimer’s dementia neuropathology following procedures previously used within the NACC database (Graff-Radford et al., 2016; Alosco et al., 2017). All findings remained the same (see Supplementary Tables 2 and 3). Original four-category ordinal classifications were therefore retained due to their superior precision.

In follow-up models, we adjusted for the presence of infarcts, lacunes and microinfarcts and for CAA along all paths. In addition, in the subset of the sample with available blood pressure data, we explored the direct and indirect effects of continuous measures of systolic and diastolic blood pressure on Alzheimer’s dementia neuropathology through circle of Willis atherosclerosis. Some research has suggested a quadratic relationship between late-life blood pressure and cognitive impairment, with both lower and higher blood pressure associated with worse cognition (Glynn et al., 1999; Morris et al., 2002). Therefore, we tested for both linear and quadratic effects in these models. Blood pressure measurements were standardized to facilitate parameter interpretation and anti-hypertensive medication use was included as an additional covariate in these blood pressure models. Finally, to explore other neuropathologies commonly observed in Alzheimer’s dementia, we also evaluated indirect effects of hypertension through circle of Willis atherosclerosis on diffuse amyloid-beta plaques and CAA.

Alpha level was set at $P < 0.05$, two-tailed for all tests. To address concerns about alpha rate inflation in the context of multiple statistical tests, Benjamini and Hochberg’s procedure was used to control for the false discovery rate (Benjamini and Hochberg, 1995). False discovery rate was controlled at 0.05 and 0.10 and was applied separately to the overall sample and after stratification of the overall sample by clinical diagnosis. MPlus version 8.1 was used for joint simultaneous modelling.

**Data availability**

The data used in this study are openly available upon request from the NACC at https://www.alz.washington.edu.

**Results**

**Demographic, vascular risk factor and neuropathological characteristics**

As expected, the Alzheimer’s dementia group exhibited greater neuritic plaque and NFT pathology and was at a more advanced clinical stage on the Clinical Dementia Rating Scale Sum of Boxes than the normal cognition group, while the MCI group exhibited levels of Alzheimer’s dementia neuropathology and clinical stage intermediate to the other two groups (see Table 1). In addition, individuals in the Alzheimer’s dementia group were more likely to have at least one APOE ε4 allele than the MCI and normal cognition groups. The Alzheimer’s dementia group was less likely to have hypertension, diabetes, congestive heart failure and atrial fibrillation compared to MCI and normal cognition groups. Regarding vascular neuropathology, the Alzheimer’s dementia group was less likely to have microinfarcts than the MCI group but had a greater degree of CAA than MCI and normal cognition groups. On demographic characteristics, the Alzheimer’s dementia group was younger and less likely to be female than both MCI and normal cognition groups and slightly less educated than the normal cognition group.
**Table 1** Comparisons across clinical diagnostic groups

| Demographics | Normal cognition (n = 372) | MCI (n = 239) | Alzheimer's dementia (n = 1587) | Omnibus test | P-value |
|--------------|-----------------------------|---------------|---------------------------------|--------------|---------|
| **Age at last visit (years)** | 84.25 (9.49) | 86.64 (11.02) | 79.01 (10.89) | F(2,195) = 56.29 | <0.001 |
| **Education (years)** | 15.59 (2.89) | 15.33 (3.04) | 15.10 (3.25) | F(2,198) = 3.66 | 0.026 |
| **Interval between last visit and death (months)** | 11.80 (8.02) | 12.11 (8.76) | 12.02 (9.08) | F(2,195) = 0.11 | 0.894 |
| **Sex (% female)** | 217 (58.3) | 122 (31.0) | 697 (43.9) | χ² = (2.198) = 26.77 | <0.001 |
| **Race/ethnicity (non-Hispanic White)** | 14 (3.8) | 6 (2.5) | 89 (5.6) | χ² = (2.198) = 5.59 | 0.061 |
| **APOE ε4 (%)** | 83 (22.3) | 63 (26.4) | 896 (56.3) | χ² = (2.198) = 188.58 | <0.001 |
| **Clinical Dementia Rating Scale sum of boxes** | 0.15 (0.51) | 1.83 (1.65) | 12.48 (5.08) | F(2,1644) = 1595.01 | <0.001 |
| **Vascular risk factors** | | | | | |
| **Hypertension (%)** | 307 (82.5) | 184 (77.0) | 1001 (63.1) | χ² = (2.198) = 53.96 | <0.001 |
| **Systolic blood pressure** | 131.62 (19.09) | 129.39 (17.91) | 128.78 (19.82) | F(2,1644) = 2.75 | 0.064 |
| **Diastolic blood pressure** | 70.75 (11.08) | 71.34 (10.19) | 72.01 (10.85) | F(2,1644) = 1.84 | 0.160 |
| **Diabetes (%)** | 57 (15.3) | 28 (11.7) | 162 (10.2) | χ² = (2.198) = 7.97 | 0.019 |
| **Hypercholesterolaemia (%)** | 195 (52.4) | 121 (50.6) | 840 (52.9) | χ² = (2.198) = 0.45 | 0.800 |
| **Congestive heart failure (%)** | 56 (15.1) | 35 (14.6) | 100 (63.1) | χ² = (2.198) = 41.08 | <0.001 |
| **Atrial fibrillation (%)** | 80 (21.5) | 46 (19.2) | 198 (12.5) | χ² = (2.198) = 23.88 | <0.001 |
| **Heart attack (%)** | 50 (13.4) | 28 (11.7) | 159 (10.0) | χ² = (2.198) = 3.91 | 0.141 |
| **Current smoking (%)** | 14 (3.8) | 7 (2.9) | 34 (2.1) | χ² = (2.198) = 3.45 | 0.179 |
| **Transient ischaemic attack (%)** | 35 (9.4) | 29 (12.1) | 128 (8.1) | χ² = (2.198) = 4.57 | 0.102 |
| **Vascular neuropathy** | | | | | |
| **Atherosclerosis** | | | | | |
| None | 73 (19.6) | 43 (18.0) | 344 (21.7) | | |
| Mild | 134 (36.0) | 86 (36.0) | 620 (39.1) | | |
| Moderate | 119 (32.0) | 83 (34.7) | 446 (28.1) | | |
| Severe | 46 (12.4) | 27 (11.3) | 177 (11.2) | | |
| **Cerebral amyloid angiopathy** | | | | | |
| None | 209 (57.9) | 130 (55.8) | 445 (28.7) | χ² = (2.198) = 166.61 | <0.001 |
| Mild | 98 (27.1) | 55 (23.6) | 497 (32.1) | | |
| Moderate | 40 (11.1) | 31 (13.3) | 384 (24.8) | | |
| Severe | 14 (3.9) | 17 (7.3) | 224 (14.5) | | |
| **Infarcts/scar (positive)** | 69 (18.5) | 53 (22.6) | 274 (17.3) | χ² = (2.198) = 3.48 | 0.176 |
| **Microinfarcts (positive)** | 75 (20.2) | 65 (27.2) | 278 (17.5) | χ² = (2.198) = 13.02 | 0.001 |
| **Alzheimer's disease neuropathology** | | | | | |
| **Consortium to Establish a Registry for Alzheimer's Disease plaque score** | | | | | |
| None | 170 (45.7) | 70 (29.3) | 127 (8.0) | | |
| Sparse | 85 (22.8) | 62 (25.9) | 152 (9.6) | | |
| Moderate | 70 (18.8) | 56 (23.4) | 305 (19.2) | | |
| Frequent | 47 (12.6) | 51 (21.3) | 1003 (63.2) | | |
| **Braak tangle stage** | | | | | |
| Stage 0 | 28 (7.5) | 12 (5.0) | 40 (2.5) | | |
| Stage I-II | 175 (47.0) | 65 (27.2) | 128 (8.1) | | |
| Stage III-IV | 140 (37.6) | 109 (45.6) | 276 (17.4) | | |
| Stage V-VI | 29 (7.8) | 53 (22.2) | 1143 (55.7) | | |

APOE ε4 = apolipoprotein epsilon 4 allele; MCI = mild cognitive impairment. Superscripts denote significant post-hoc differences between each diagnostic group and the class number indicated (1 = Normal Cognition, 2 = Mild Cognitive Impairment, 3 = Alzheimer’s Dementia). Based on sample of 1647 cases.

**Direct and indirect effects of hypertension on Alzheimer’s disease neuropathology**

In the overall sample, there were significant associations of hypertension with circle of Willis atherosclerosis (t = 2.707, P = 0.007, OR = 1.29) and circle of Willis atherosclerosis with neuritic plaques (t = 3.643, P < 0.001, OR = 1.20) and NFTs (t = 2.393, P = 0.017, OR = 1.13), leading to significant indirect effects of hypertension on neuritic plaques (OR = 1.01, 95% CI = 1.004-1.03) and NFTs (OR = 1.01, 95% CI = 1.001-1.02) (see Table 2). In addition, there was a significant negative association of hypertension with neuritic plaques (t = −3.074, P = 0.002, OR = 0.73) and NFTs (t = −2.292, P = 0.022, OR = 0.82) along the direct path. Thus, hypertension was associated with greater Alzheimer’s dementia neuropathology through its effect on circle of Willis atherosclerosis, but after adjusting for this effect, was associated with less Alzheimer’s dementia neuropathology. 
through its direct effect. Statistical significance of all of the results described above was retained using a 0.05 false discovery rate.

After stratification by clinical group, there were again significant associations of hypertension with circle of Willis atherosclerosis ($t = 2.471, P = 0.013, OR = 1.29$) and of circle of Willis atherosclerosis with neuritic plaques ($t = 4.290, P < 0.001, OR = 1.31$) and NFTs ($t = 2.382, P = 0.017, OR = 1.18$), leading to significant indirect effects of hypertension on neuritic plaques (OR = 1.01, 95% CI = 1.003–1.03) and NFTs (OR = 1.01, 95% CI = 1.001–1.02). However, hypertension was not associated with neuritic plaques or NFTs along the direct path. In addition, there were no significant direct or indirect effects within MCI or normal cognition groups. After correction for false discovery rate at 0.05, only the association between circle of Willis atherosclerosis and neuritic plaques remained significant. No additional associations were significant when false discovery rate was controlled at 0.10.

Adjustment for the presence of infarcts, lacunes or microinfarcts (see Supplementary Table 4) and for CAA (see Supplementary Table 5) had minimal impact on modelled associations.

**Direct and indirect effects of blood pressure on Alzheimer’s disease neuropathology**

In the overall sample, there were no significant linear or quadratic effects of systolic blood pressure on neuritic plaques or NFTs along the direct pathway, nor was there a significant quadratic effect of hypertension on circle of Willis atherosclerosis (see Table 3). In contrast, there were significant linear associations of systolic blood pressure with circle of Willis atherosclerosis ($t = 2.643, P = 0.008, OR = 1.13$) and of circle of Willis atherosclerosis with neuritic plaques ($t = 2.989, P = 0.003, OR = 1.19$) and NFTs ($t = 2.243, P = 0.025, OR = 1.14$), resulting in significant indirect effects of hypertension on neuritic plaques (OR = 1.01, 95% CI = 1.001–1.01) and NFTs (OR = 1.003, 95% CI = 1.001–1.01) through circle of Willis atherosclerosis. All significant associations described above remained significant when false discovery rate was set at 0.10. In contrast, only associations between systolic blood pressure and circle of Willis atherosclerosis and of circle of Willis atherosclerosis with neuritic plaques remained significant when false discovery rate was limited to 0.05.

Similarly, within the Alzheimer’s dementia group, there was a significant positive linear association of systolic blood pressure with circle of Willis atherosclerosis ($t = 2.211, P = 0.027, OR = 1.13$) and a significant positive association of circle of Willis atherosclerosis with neuritic plaques ($t = 3.788, P < 0.001, OR = 1.34$) and NFTs ($t = 2.393, P = 0.017, OR = 1.22$), leading to significant indirect effects of systolic blood pressure through circle of Willis atherosclerosis on both neuritic plaques (OR = 1.01, 95% CI = 1.001–1.02) and NFTs (OR = 1.003, 95% CI = 1.001–1.01). However, there were no significant quadratic effects of systolic blood pressure on circle of Willis atherosclerosis and neither quadratic nor linear associations of systolic blood pressure with neuritic plaques or NFTs were significant along the direct path. Only the association of circle of Willis atherosclerosis with neuritic plaque pathology remained significant after false discovery rate correction at 0.05 and 0.10.

For diastolic blood pressure in the overall sample, there was a significant quadratic association between hypertension and neuritic plaque pathology ($t = -2.053, P = 0.040, OR = 0.95$) along the direct pathway, in which high (82.49 mm Hg) ($t = -2.092, P = 0.036$) but not average (71.67 mm Hg) ($t = 0.000, P = 1.000$) or low (60.85 mm Hg) ($t = 0.240, P = 0.810$) diastolic blood pressure was associated with less neuritic plaque

| Table 2 Direct and indirect effects of hypertension on circle of Willis atherosclerosis and Alzheimer's disease neuropathology |
|---------------------------------------------------------------|
| **Overall sample (N = 2198)**                                  |
| Neuritic plaques                                             | 1.29 (1.07–1.54)** | 1.20 (1.09–1.32)** | 0.73 (0.59–0.89)** | 1.01 (1.004–1.03)** |
| Neurofibrillary tangles                                      | 1.29 (1.07–1.54)** | 1.13 (1.02–1.24)*  | 0.82 (0.62–0.97)*  | 1.01 (1.001–1.02)*  |
| **Alzheimer's dementia sample (N = 1587)**                   |
| Neuritic plaques                                             | 1.29 (1.05–1.58)*  | 1.31 (1.15–1.47)** | 0.85 (0.67–1.04)*  | 1.01 (1.003–1.03)*  |
| Neurofibrillary tangles                                      | 1.29 (1.05–1.58)*  | 1.18 (1.03–1.35)*  | 0.94 (0.71–1.22)*  | 1.01 (1.001–1.02)*  |
| **MCI sample (N = 239)**                                     |
| Neuritic plaques                                             | 1.15 (0.54–2.50)   | 0.97 (0.69–1.36)   | 0.98 (0.45–2.18)   | 1.00 (0.95–1.03)   |
| Neurofibrillary tangles                                      | 1.15 (0.54–2.50)   | 1.13 (0.76–1.58)   | 1.53 (0.66–3.27)   | 1.00 (0.98–1.05)   |
| **Normal cognition sample (N = 372)**                        |
| Neuritic plaques                                             | 1.63 (0.95–2.75)   | 1.00 (0.80–1.26)   | 0.70 (0.40–1.25)   | 1.00 (0.94–1.04)   |
| Neurofibrillary tangles                                      | 1.63 (0.95–2.75)   | 0.85 (0.67–1.08)   | 0.98 (0.54–1.73)   | 0.99 (0.94–1.003)  |

All analyses adjusted for age, sex, APOE ε4, non-White race and other vascular risk factors; parenthetical values for the HTN → atherosclerosis → ADNP path reflect a 95% bias-corrected bootstrapped confidence interval; ADNP = Alzheimer’s disease neuropathology; HTN = hypertension; MCI = mild cognitive impairment.

*P < 0.05; **P < 0.01; ***P < 0.001.
Table 3 Direct and indirect effects of systolic blood pressure on circle of Willis atherosclerosis and Alzheimer's disease neuropathology

|                          | HTN → atherosclerosis | Atherosclerosis → ADNP | HTN → ADNP | HTN → atherosclerosis → ADNP |
|--------------------------|------------------------|------------------------|------------|------------------------------|
| Overall sample (N = 1647) |                        |                        |            |                              |
| Neuritic plaques         | 1.13 (1.03–1.23)       | 1.19 (1.03–1.23)       | 0.99 (0.90–1.10) | 1.01 (1.001–1.01)            |
| Neurofibrillary tangles  | 1.13 (1.03–1.23)       | 1.14 (1.01–1.29)       | 0.94 (0.85–1.29) | 1.003 (1.001–1.01)           |
| Alzheimer's dementia sample (N = 1114) |   |                        |            |                              |
| Neuritic plaques         | 1.13 (1.02–1.26)       | 1.34 (1.15–1.57)       | 0.95 (0.83–1.08) | 1.01 (1.01–1.02)             |
| Neurofibrillary tangles  | 1.13 (1.02–1.26)       | 1.22 (1.03–1.42)       | 0.92 (0.81–1.06) | 1.003 (1.001–1.01)           |
| MCI sample (N = 198)     |                        |                        |            |                              |
| Neuritic plaques         | 1.15 (0.82–1.58)       | 0.85 (0.58–1.26)       | 1.34 (0.94–1.77) | 0.99 (0.95–1.01)             |
| Neurofibrillary tangles  | 1.15 (0.82–1.58)       | 1.10 (0.72–1.61)       | 1.24 (0.87–1.70) | 1.00 (0.99–1.03)             |
| Normal cognition sample (N = 335) |  |                        |            |                              |
| Neuritic plaques         | 1.21 (0.96–1.52)       | 0.97 (0.76–1.23)       | 1.18 (0.94–1.49) | 1.00 (0.97–1.01)             |
| Neurofibrillary tangles  | 1.21 (0.96–1.52)       | 0.85 (0.66–1.10)       | 1.09 (0.86–1.38) | 0.99 (0.98–1.001)            |

All analyses adjusted for age, sex, presence of APOE ε4 allele, non-White race, other vascular risk factors and use of any anti-hypertensive medication; parenthetical values for the HTN → atherosclerosis → ADNP path reflect a 95% bias-corrected bootstrapped confidence interval; ADNP = Alzheimer’s disease neuropathology; HTN = hypertension; MCI = mild cognitive impairment.

*p < 0.05; **p < 0.01; ***p < 0.001.

Table 4 Direct and indirect linear effects of diastolic blood pressure on circle of Willis atherosclerosis and Alzheimer’s disease neuropathology

|                          | HTN → atherosclerosis | Atherosclerosis → ADNP | HTN → ADNP | HTN → atherosclerosis → ADNP |
|--------------------------|------------------------|------------------------|------------|------------------------------|
| Overall sample (N = 1647) |                        |                        |            |                              |
| Neuritic plaques         | 1.11 (1.00–1.23)       | 1.20 (1.07–1.35)       | 0.94 (0.84–1.03) | 1.01 (1.001–1.01)            |
| Neurofibrillary tangles  | 1.11 (1.00–1.23)       | 1.14 (1.01–1.28)       | 0.92 (0.83–1.03) | 1.01 (1.001–1.01)           |
| Alzheimer’s dementia sample (N = 1114) |   |                        |            |                              |
| Neuritic plaques         | 1.14 (1.00–1.28)       | 1.35 (1.16–1.57)       | 0.89 (0.76–1.00) | 1.01 (1.01–1.02)             |
| Neurofibrillary tangles  | 1.14 (1.00–1.28)       | 1.22 (1.04–1.43)       | 0.89 (0.77–1.02) | 1.004 (1.001–1.01)           |
| MCI sample (N = 198)     |                        |                        |            |                              |
| Neuritic plaques         | 1.06 (0.72–1.51)       | 0.86 (0.59–1.27)       | 1.25 (0.87–1.74) | 1.00 (0.96–1.01)             |
| Neurofibrillary tangles  | 1.06 (0.72–1.51)       | 1.11 (0.73–1.62)       | 1.15 (0.80–1.66) | 1.00 (0.99–1.02)             |
| Normal cognition sample (N = 335) |  |                        |            |                              |
| Neuritic plaques         | 1.06 (0.83–1.31)       | 0.98 (0.77–1.25)       | 0.95 (0.75–1.20) | 1.00 (0.99–1.01)             |
| Neurofibrillary tangles  | 1.06 (0.83–1.31)       | 0.86 (0.67–1.11)       | 0.90 (0.73–1.14) | 1.00 (0.99–1.003)            |

All analyses adjusted for age, sex, presence of APOE ε4 allele, non-White race, other vascular risk factors and use of any anti-hypertensive medication; parenthetical values for the HTN → atherosclerosis → ADNP path reflect a 95% bias-corrected bootstrapped confidence interval; ADNP = Alzheimer’s disease neuropathology; HTN = hypertension; MCI = mild cognitive impairment.

*A significant non-linear direct effect of diastolic blood pressure on neuritic plaques was included in this model (t = 2.186, P = 0.04, OR = 0.95).

*p < 0.05; **p < 0.01; ***p < 0.001.

pathology (see Table 4). In contrast, neither quadratic associations between diastolic blood pressure and NFTs nor linear associations between diastolic blood pressure and neuritic plaques and NFTs were significant. Along the indirect pathway, there were significant associations of circle of Willis atherosclerosis with neuritic plaques (t = 3.140, P = 0.002, OR = 1.20) and NFTs (t = 2.350, P = 0.019, OR = 1.14); however, associations of hypertension with circle of Willis atherosclerosis failed to achieve significance (t = 1.952, P = 0.051, OR = 1.11), leading to non-significant indirect effects of diastolic blood pressure on neuritic plaques (OR = 1.01, 95% CI = 1.00–1.01) and NFTs (OR = 1.01, 95% CI = 1.00–1.01). Significant associations of circle of Willis atherosclerosis with neuritic plaques and NFTs were maintained at a false discovery rate of 0.10. In contrast, only the association between circle of Willis atherosclerosis and neuritic plaques was maintained at false discovery rate of 0.05.

After stratification by clinical diagnosis, linear direct effects on neuritic plaques and NFTs were again non-significant within the Alzheimer’s dementia group (see Table 4). There was, however, a significant negative quadratic association of diastolic blood pressure with neuritic plaques (t = –2.186, P = 0.029, OR = 0.94), in which diastolic blood pressure was associated with less neuritic plaque pathology at high diastolic blood pressure levels (>82.86 mm Hg) (t = –2.730, P = 0.006, OR = 0.83), but not at average (72.01 mm Hg) (t = –1.730, P = 0.084, OR = 1.00) or low levels (61.16 mm Hg)
(t = 0.605, P = 0.545, OR = 1.05). Regarding indirect effects, there was a significant positive linear association of diastolic blood pressure with circle of Willis atherosclerosis (t = 1.988, P = 0.047, OR = 1.14) and of circle of Willis atherosclerosis with neuritic plaques (t = 3.950, P < 0.001, OR = 1.36) and NFTs (t = 2.425, P = 0.015, OR = 1.22), leading to significant indirect effects of diastolic blood pressure on neuritic plaques (OR = 1.01, 95% CI = 1.001–1.02) and NFTs (OR = 1.004, 95% CI = 1.001–1.01). Following false discovery rate correction at 0.05 and 0.10, only the association of circle of Willis atherosclerosis with neuritic plaques remained significant.

In contrast, there were no significant direct or indirect effects of systolic or diastolic blood pressure on neuritic plaques or NFTs within MCI and normal cognition groups.

**Direct and indirect effects of hypertension on diffuse plaques and cerebral amyloid angiopathy**

Similar to findings for core Alzheimer’s dementia neuropathologies (i.e. neuritic plaques and NFT), there was evidence of indirect effects of hypertension through circle of Willis atherosclerosis on both diffuse plaques (OR = 1.01, 95% CI = 1.002–1.01) and CAA (OR = 1.01, 95% CI = 1.001–1.01) in the overall sample and within the Alzheimer’s dementia group (see Table 5). There were also significant negative direct effects of hypertension on CAA in the overall sample (t = −2.557, P = 0.011, OR = 0.78), but not for diffuse plaques. After correction for multiple comparisons, all associations within the overall sample remained significant at 0.05 and 0.10 levels, while associations of within the Alzheimer’s dementia group were no longer significant.

### Discussion

This study evaluated direct and indirect effects of hypertension through circle of Willis atherosclerosis on Alzheimer’s dementia neuropathology in a large autopsy-based sample of 2198 decedents. In the overall sample, hypertension was associated with increased circle of Willis atherosclerosis, which was in turn associated with greater neuritic plaque and NFT pathology, leading to significant indirect effects of hypertension on Alzheimer’s dementia neuropathology through circle of Willis atherosclerosis. In contrast, after adjustment for these indirect effects, hypertension was associated with less neuritic plaque and NFT pathology along the direct pathway. Following stratification of the sample by clinical diagnosis, similar indirect effects were observed among individuals with Alzheimer’s dementia. These effects remained significant after adjusting for cerebral infarction and CAA and similar indirect effects were observed for continuous measures of both systolic and diastolic blood pressure. Similarly, we also observed significant indirect effects of hypertension on diffuse plaques and CAA through circle of Willis atherosclerosis in the overall sample and within the Alzheimer’s dementia sample. In contrast, neither direct nor indirect effects of hypertension, systolic blood pressure or diastolic blood pressure on Alzheimer’s dementia neuropathology were found within normal cognition or MCI groups.

These results are consistent with several previous findings. For one, prior research has also shown that hypertension contributes to atherosclerosis, presumably by injuring the vascular endothelium and triggering an atherogenic inflammatory response (Ross, 1993). For another, several previous studies have found that circle of Willis atherosclerosis is associated with increased neuritic plaque and NFT pathology (Roher et al., 2003; Honig et al., 2003; Honig et al., 2003).
mentia neuropathology by limiting blood flow reductions. Blood pressure may be protective against Alzheimer’s disease. Levels of diastolic blood pressure were associated with greater Alzheimer’s dementia neuropathology, in which high diastolic blood pressure lived long enough to be included in the NACC-Neuropathological Data Set. Replication of this finding is needed to disentangle these competing explanations.

Overall, the current study suggests that hypertension and higher late-life blood pressure levels may promote Alzheimer’s dementia pathology indirectly through their effects on circle of Willis atherosclerosis. Previous research has shown that hypertension may contribute to Alzheimer’s dementia pathogenesis through atherosclerosis-dependent pathways involving cerebral hypoperfusion and diminished perivascular clearance (Gupta and Laedecola, 2015) and atherosclerosis-independent pathways involving increased influx of Aβ from the blood into the brain (Carnevale et al., 2012) and diminished Aβ catabolism (Miners et al., 2011; Ashby et al., 2016). In the current study, the impact of hypertension on Alzheimer’s dementia pathology along the atherosclerosis-independent pathway (i.e. the direct effect) was not associated with greater Alzheimer’s dementia neuropathology. This finding suggests that these latter two mechanisms may be less impactful than those involving cerebral hypoperfusion and Aβ clearance.

Similar mechanisms may also underlie the relationship between hypertension and CAA. CAA is present in up to 80% of Alzheimer’s dementia cases (Jellinger, 2002). Previous research has suggested that hypertension may promote CAA through its disruption of vessel wall integrity and consequent role in reducing cerebral blood flow and impairing Aβ clearance (Weller et al., 2008; Okamoto et al., 2012; Shah et al., 2012; Hawkes et al., 2014; Jandke et al., 2018). Given the involvement of circle of Willis atherosclerosis in both of these mechanisms and the observation of an indirect effect of hypertension on CAA through circle of Willis atherosclerosis in this study, circle of Willis atherosclerosis may also represent an important area of convergence for hypertension and CAA.

The current study is subject to a few limitations. Data used in this study were cross-sectional. As such, the direction of influence between hypertension, circle of Willis atherosclerosis and Alzheimer’s dementia pathology cannot be definitively demonstrated. In addition, this study may be subject to an ascertainment bias. Decedents in this sample were also relatively healthy, especially in the Alzheimer's dementia group, which may reflect recruitment procedures that excluded individuals with elevated cerebrovascular risk. In addition, as discussed earlier, the current sample may be subject to a survivor bias given that hypertension is associated with premature mortality (Danaei et al., 2009). These latter two limitations may have attenuated effect sizes in the current study and as such, these effects sizes may represent lower-end estimates. Some significant effects failed to survive correction.
for false discovery rate, although, importantly, all significant effects observed in the overall sample remained significant after correction. Main analyses in this study also relied on self-reported hypertension, which may be subject to error. Notably, however, findings were replicated using objective measures of systolic and diastolic blood pressure, suggesting that self-report error did not account for observed effects. Also, neuropathological assessment protocols varied across individual ADCs, which may have reduced reliability of classifications. However, neuropathological data were collected using consensus guidelines and entered into a standardized Neuropathology Form and Coding Guidebook. Further, main analyses remained significant when using alternative dichotomous classifications of circle of Willis atherosclerosis, neuritic plaques and NFTs that were intended to improve reliability (Graff-Radford et al., 2016; Alosco et al., 2017). Finally, there were large differences in sample sizes across clinical groups, which may have limited power to detect effects in the MCI and normal cognition groups.

Future research should explore indirect effects of other vascular risk factors on Alzheimer’s dementia neuropathology through circle of Willis atherosclerosis. Prospective longitudinal studies incorporating in vivo measures of intracranial atherosclerosis and Alzheimer’s dementia pathology would help clarify the time course and direction of influence between vascular risk factors, atherosclerosis and Alzheimer’s dementia pathology. Additional studies exploring these processes in samples enriched for mixed Alzheimer’s dementia/vascular neuropathology may elucidate additional effects. Ultimately, further clarification of intermediate pathways linking vascular risk factors to Alzheimer’s dementia may facilitate identification of important intervention targets. In conclusion, this is the largest study to date to explore the impact of hypertension on post-mortem Alzheimer’s dementia neuropathology. Hypertension was found to increase Alzheimer’s dementia neuropathology indirectly through its effect on circle of Willis atherosclerosis. This effect could be due to persistent cerebral hypoperfusion leading to Aβ production and tau phosphorylation or diminished clearance of Aβ. Circle of Willis atherosclerosis may be an important point of convergence between vascular risk factors, cerebrovascular changes and Alzheimer’s dementia neuropathology.

**Supplementary material**

Supplementary material is available at Brain Communications online.

**Acknowledgements**

The authors are grateful to the NACC study investigators and participants for providing the data used in this article.

**Funding**

This manuscript was supported by grants from VA Clinical Science Research & Development (Merit Award 1101CX001842 to K.J.B.), the Alzheimer’s Association (AARG-18-566254 to K.J.B.), the Dana Foundation (to K.J.B.), and the National Institute on Aging of the National Institutes of Health (R01 AG063782 to K.J.B. and K24 AG026431 and R01 AG049810 to M.W.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The NACC database is funded by National Institute on Aging of the National Institutes of Health Grant U01 AG016976. NACC data are contributed by the National Institute on Aging funded Alzheimer’s Disease Centers: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016370 (PI Marie-Francoise Chesnelet, MD, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG023838 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD).

**Competing interests**

G.M.L.E., A.J.W., D.A.N., and K.J.B. report no competing interests. M.W.B. is a paid consultant for Eisai, Novartis and Roche Pharmaceuticals and receives royalties from Oxford University Press.

**References**

Alosco ML, Duskin J, Besser LM, Martin B, Chaisson CE, Gunstad J, et al. Modeling the relationships among late-life body mass index, cerebrovascular disease, and Alzheimer’s disease neuropathology in an autopsy sample of 1,421 subjects from the National Alzheimer’s Coordinating Center Data Set. J Alzheimers Dis 2017; 57: 953–68.
Arvanitakis Z, Capuano AW, Lamar M, Shah RC, Barnes LL, Bennett DA, et al. Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology. Neurology 2018; 91: e517–25.

Ashby EL, Miners JS, Kehoe PG, Love S. Effects of hypertension and anti-hypertensive treatment on amyloid-b (Aβ) plaque load and Aβ-synthesizing and Aβ-degrading enzymes in frontal cortex. J Alzheimers Dis 2016; 50: 1191–203.

Beach TG, Wilson JB, Sue LJ, Newell A, Poston M, Casneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neurtic plaques and neurofibrillar tangles. Acta Neuropathol 2007; 113: 13–21.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289–300.

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59.

Carnevale D, Masico G, D’Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012; 60: 188–97.

Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011; 91: 327–87.

Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer’s disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther 2012; 4: 1.

Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009; 6: e1000058.

Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68: 231–40.

Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. JAMA 1999; 281: 438–45.

Gorelick PB, Nyenhuis D, Materson BJ, Calhoun DA, Elliott WJ, Phillips RA, et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens 2012; 6: 109–15.

Graff-Radford NR, Besser LM, Crook JE, Kukull WA, Dickson DW. Neuropathologic differences by race from the National Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of the pathological stages of Alzheimer’s disease in thin paraffin sections: a comparative study. Dement Geriatr Cogn Disord 2003; 15: 162–75.

Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology 2005; 64: 494–500.

Hughes TM, Kulier LH, Barinas-Mitchell EJ, McDade EM, Klunk WE, Cohen AD, et al. Arterial stiffness and beta-amyloid progression in nondemented elderly adults. JAMA Neurol 2014; 71: 562–8.

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012; 8: 1–13.

Ingall TJ, Homer D, Baker HL Jr, Kortke BA, O’Fallon WM, Whisnant JP. Predictors of intracranial carotid artery atherosclerosis. Duration of cigarette smoking and hypertension are more powerful than serum lipid levels. Arch Neurol 1991; 48: 687–91.

Itoh Y, Yamada M, Sodeyama N, Suematsu N, Matsushita M, Otomo E, et al. Atherosclerosis is not implicated in association of APOE epsilon4 with AD. Neurology 1999; 53: 236–7.

Jandke S, Garz C, Schwanke D, Sendtner M, Heinz HJ, Carare RO, et al. The association between hypertensive arteriopathy and cerebral amyloid angiopathy in spontaneously hypertensive stroke-prone rats. Brain Pathol 2018; 28: 844–59.

Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813–36.

Jennings JR, Muldoon MF, Ryan C, Price JC, Greer P, Sutton-Tyrrell K, et al. Reduced cerebral blood flow response and compensation among patients with untreated hypertension. Neurology 2005; 64: 1358–65.

Kalback W, Esh C, Castaño EM, Rahman A, Kokjohn T, Luehrs DC, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer’s disease. Neurol Res 2004; 26: 525–39.

Koike MA, Green KN, Blumenthon-Jones M, Lefler FM. Oligemic hypoperfusion differentially affects tau and amyloid-[beta]. Am J Pathol 2010; 177: 300–10.

Kosunen O, Talasoini S, Lehtovirta M, Heinonen O, Helisalmi S, Mannnermaa A, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 1995; 26: 743–8.

Langbaum JB, Chen K, Launer LJ, Fleisher AS, Lee W, Liu X, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging 2012; 33: 827.e11–9.

Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49–55.

Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 2009; 30: 1091–8.

MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol 2007; 58: 593–614.

MacKinnon DP, Lockwood CM, Williams J. Confidence limits for the indirect effect: distribution of the product and resampling methods. Multivariate Behav Res 2004; 39: 99–128.

Matsushita K, Kuriyama Y, Nagatsu K, Nakamura M, Sawada T, Omae T. Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 1994; 23: 565–8.

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441–50.

Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011; 70: 944–59.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991; 41: 479–86.

Mitchell GF. Arterial stiffness and hypertension. Hypertension 2014; 64: 13–8.

Morris MC, Scherr PA, Hebert LE, Bennett DA, Wilson RS, Glynn RJ, et al. Association between blood pressure and cognitive function in a biracial community population of older persons. Neuroepidemiology 2002; 21: 123–30.

Nagy Z, Yilmazer-Hanke DM, Braak H, Braak E, Schulz C, Hanke J. Assessment of the pathological stages of Alzheimer’s disease in thin paraffin sections: a comparative study. Dement Geriatr Cogn Disord 1998; 9: 140–4.

Nation DA, Wierenga CE, Clark LR, Dev SI, Stricker NH, Jak AJ, et al. Cortical and subcortical cerebrovascular resistance index in
mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2013; 36: 689–98.
Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, Hase Y, et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123: 381–94.
Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990; 2 (Summer): 161–92.
Petrovitch H, White LR, Izmirlian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 57–62.
Rodrique KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC. Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600–6.
Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055–62.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.
Schley D, Carare-Rnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 2006; 238: 962–74.
Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012; 59: 780–6.
Skoog I, Lernfelt B, Landahl S, Palmertz B, Andresson LA, Nilsson L, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC 3rd. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162–9.
Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007; 54: 721–37.
Toledo JB, Toledo E, Weiner MW, Jack CR Jr, Jagust W, Lee VM, et al. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2012; 8: 483–9.
Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep 2017; 19: 24.
Wang X, Xing A, Xu C, Cai Q, Liu H, Li L. Cerebrovascular hypoperfusion induces spatial memory impairment, synaptic changes, and amyloid-β oligomerization in rats. J Alzheimers Dis 2010; 21: 813–22.
Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 2008; 18: 253–66.
Yarchoan M, Xie SX, Kung MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135: 3749–56.
Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, et al. Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007; 282: 10873–80.
Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. Stroke 2013; 44: 2835–41.
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011; 12: 723–38.